FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 11:37:42 2024-05-17 EDT | ||
| 2.6 EUR | +2.36% |
|
| Current month | -2.62% | ||
| 1 month | -37.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 2.6 | +2.36% |
| 24-05-16 | 2.54 | +0.79% |
| 24-05-15 | 2.52 | +3.70% |
| 24-05-14 | 2.43 | +0.41% |
| 24-05-13 | 2.42 | +2.11% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 11:37 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SN34ZF |
| ISIN | DE000SN34ZF5 |
| Date issued | 2022-06-29 |
| Strike | 10,743 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.46 € |
|---|---|
| Lowest since issue | 2.34 € |
| Spread | 0.07 € |
| Spread % | 2.64% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Certificates
- Certificat